Biomedical Engineering Reference
In-Depth Information
141. Chan, A.K. et al., Covalent antithrombin-heparin complexes with high anticoagulant activity: Intrave-
nous, subcutaneous and intratracheal administration,
J. Biol. Chem
., 272, 22111, 1997.
142. Rosenberg, R.D. et al., Highly active heparin species with multiple binding sites for antithrombin,
Biochem. Biophys. Res. Comm
., 86, 1319, 1979.
143. Thunberg, L. et al., On the molecular-weight-dependence of the anticoagulant activity of heparin,
Biochem
.
J
., 181, 241, 1979.
144. Oscarsson, L.G., Pejler, G., and Lindahl, U., Location of the antithrombin-binding sequence in the hepa-
rin chain,
J. Biol. Chem
., 264, 296, 1989.
145. Laurent, T.C. et al., The molecular-weight-dependence of the anti-coagulant activity of heparin,
Biochem. J
., 175, 691, 1978.
146. Berry, L.R. and Hatton, M.W., Controlled depolymerization of heparin: Anticoagulant activity and
molecular size of the products,
Biochem. Soc. Trans
., 11, 101, 1983.
147. Berry, L.R. et al., Selective cleavage of heparin using aqueous 2-hydroxypyridine: Production of an
aldose-terminating fragment with high anticoagulant activity,
Biochem. Biophys. Res. Comm
., 346,
946, 2006.
148. Petitou, M. et al., Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide
O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4)-O-(beta-D-glucopyranosyluronic
acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glucopyranosyl)-(1-4)-O-(2-O-sulfo-
alpha-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium
salt, a heparin fragment having high affi nity for antithrombin III,
Carb. Res
., 147, 221, 1986.
149. Kusche, M. et al., Biosynthesis of heparin. O-sulfation of the antithrombin-binding region,
J. Biol.
Chem
., 263, 15474, 1988.
150. Petitou, M. et al., Binding of heparin to antithrombin III: A chemical proof of the critical role played by
a 3-sulfated 2-amino-2-deoxy-D-glucose residue,
Carb. Res
., 179, 163, 1988.
151. Petitou, M. et al., A unique trisaccharide sequence in heparin mediates the early step of antithrombin III
activation,
Glycobiology
, 7, 323, 1997.
152. Desai, U.R. et al., Mechanism of heparin activation of antithrombin. Role of individual residues of the
pentasaccharide activating sequence in the recognition of native and activated states of antithrombin,
J. Biol. Chem
., 273, 7478, 1998.
153. Desai, U.R. et al., Mechanism of heparin activation of antithrombin: Evidence for an induced-fi t model
of allosteric activation involving two interaction subsites,
Biochemistry
, 37, 13033, 1998.
154. Arocas, V. et al., The role of Arg46 and Arg47 of antithrombin in heparin binding,
Biochemistry
, 38,
10196, 1999.
155. Kandrotas, R.J., Heparin pharmacokinetics and pharmacodynamics,
Clin. Pharmacokinet
., 22, 359,
1992.
156. e, J., Rezaie, A.R., and Esmon, C.T., Glycosaminoglycan contributions to both protein C activation and
thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93,
97, and 101,
J. Biol. Chem
., 269, 17965, 1994.
157. Petersen, L.C. and Jorgensen, M., Electrostatic interactions in the heparin-enhanced reaction between
human thrombin and antithrombin,
Biochem. J
., 211, 91, 1983.
158. Lozano, M. et al., Suitability of low molecular weight heparin(oid)s and a pentasaccharide for an
in vitro
human thrombosis model,
Arterioscler. Thromb
., 14, 1215, 1994.
159. Bergqvist, D., Low molecular weight heparins,
J. Intern. Med
., 240, 63, 1996.
160. Young, E. et al., Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding
to plasma proteins than unfractionated heparin,
Thromb. Haemost.
, 71, 300, 1994.
161. Bara, L. et al., Comparative pharmacokinetics (PK 10169) and unfractionated heparin after intravenous
and subcutaneous administration,
Thromb. Res
., 39, 631, 1985.
162. Hirsh, J. and Levine, M.N., Low molecular weight heparin,
Blood
, 79, 1, 1992.
163. Fareed, J. et al., Low molecular weight heparins: Are they different?
Can. J. Cardiol
., 14, 28E, 1998.
164. Wolzt, M. et al., Studies on the neutralizing effects of protamine on unfractionated and low molecular
weight heparin (Fragmin) at the site of activation of the coagulation system in man,
Thromb. Haemost
.,
73, 439, 1995.
165. Briant, L. et al., Unfractionated heparin and CY 216: Pharmacokinetics and bioavailabilities of the anti-
factor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit,
Thromb. Haemost
.,
61, 348, 1989.
166. Schran, H.F. et al., The pharmacokinetics and bioavailability of subcutaneously administered dihydro-
ergotamine, heparin and the dihydroergotamine-heparin combination,
Thromb. Res
., 31, 51, 1983.
